Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBITDA (2019 - 2025)

Keros Therapeutics' EBITDA history spans 7 years, with the latest figure at -$29.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 45.04% year-over-year to -$29.3 million; the TTM value through Dec 2025 reached $67.6 million, up 132.05%, while the annual FY2025 figure was $67.6 million, 132.05% up from the prior year.
  • EBITDA reached -$29.3 million in Q4 2025 per KROS's latest filing, down from -$15.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $152.0 million in Q1 2025 to a low of -$58.7 million in Q3 2024.
  • Average EBITDA over 5 years is -$24.2 million, with a median of -$31.3 million recorded in 2022.
  • Peak YoY movement for EBITDA: tumbled 556.8% in 2022, then soared 413.59% in 2025.
  • A 5-year view of EBITDA shows it stood at -$4.9 million in 2021, then crashed by 556.8% to -$32.0 million in 2022, then tumbled by 45.35% to -$46.5 million in 2023, then fell by 14.64% to -$53.3 million in 2024, then surged by 45.04% to -$29.3 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's EBITDA are -$29.3 million (Q4 2025), -$15.4 million (Q3 2025), and -$39.8 million (Q2 2025).